Trial interventions
infection
INFECTION
The intervention selected was the addition of Selective Digestive tract Decontamination (SDD) to the standard infection control strategy of the participating PICU. The intervention consisted of three topical antimicrobial agents, colistin, tobramycin and nystatin, prepared according to international standards for Good Manufacturing Procedures and manufactured in a Therapeutic Goods Administration-approved facility, Verita Pharma®, Sydney, under licence from the George Institute for Global Health, Sydney. The SDD preparations were manufactured specifically for the SuDDICU randomised controlled trial conducted in Australia and Canada between 2017 and 2023